Bicocca Open Archive

Logo unimib boa
SENNI, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 22.656
NA - Nord America 18.960
EU - Europa 11.625
SA - Sud America 3.218
Continente sconosciuto - Info sul continente non disponibili 1.733
AF - Africa 454
OC - Oceania 37
Totale 58.683
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.232
SG - Singapore 7.218
VN - Vietnam 5.020
IT - Italia 4.354
HK - Hong Kong 3.986
CN - Cina 2.984
BR - Brasile 2.440
RU - Federazione Russa 2.318
CA - Canada 1.349
IE - Irlanda 1.343
BD - Bangladesh 1.185
DE - Germania 913
SE - Svezia 611
FR - Francia 571
IN - India 455
AR - Argentina 326
GB - Regno Unito 319
FI - Finlandia 254
ID - Indonesia 247
KR - Corea 238
IQ - Iraq 189
MX - Messico 186
JP - Giappone 157
UA - Ucraina 152
AT - Austria 147
NL - Olanda 145
TR - Turchia 134
EC - Ecuador 120
ZA - Sudafrica 120
PK - Pakistan 118
ES - Italia 95
SA - Arabia Saudita 95
PH - Filippine 92
CO - Colombia 91
PL - Polonia 81
MY - Malesia 75
VE - Venezuela 69
UZ - Uzbekistan 59
MA - Marocco 58
TN - Tunisia 56
PY - Paraguay 54
BE - Belgio 48
CL - Cile 47
TH - Thailandia 44
JM - Giamaica 42
AE - Emirati Arabi Uniti 41
JO - Giordania 41
EG - Egitto 38
CR - Costa Rica 35
KE - Kenya 35
ET - Etiopia 34
NP - Nepal 30
AU - Australia 29
UY - Uruguay 29
RO - Romania 28
DK - Danimarca 27
DZ - Algeria 26
CH - Svizzera 25
IR - Iran 25
KZ - Kazakistan 25
PE - Perù 25
HU - Ungheria 23
LT - Lituania 22
PS - Palestinian Territory 22
CZ - Repubblica Ceca 21
LB - Libano 21
OM - Oman 19
IL - Israele 18
PT - Portogallo 18
HN - Honduras 17
NO - Norvegia 17
AZ - Azerbaigian 16
TT - Trinidad e Tobago 16
TW - Taiwan 16
GT - Guatemala 15
RS - Serbia 15
NI - Nicaragua 14
BO - Bolivia 13
NG - Nigeria 13
SY - Repubblica araba siriana 13
KG - Kirghizistan 11
AO - Angola 10
CI - Costa d'Avorio 10
GR - Grecia 10
QA - Qatar 10
SN - Senegal 10
SV - El Salvador 10
LV - Lettonia 9
PA - Panama 9
AL - Albania 8
BG - Bulgaria 8
DO - Repubblica Dominicana 8
KW - Kuwait 8
NZ - Nuova Zelanda 8
SK - Slovacchia (Repubblica Slovacca) 8
BH - Bahrain 7
BW - Botswana 7
GE - Georgia 7
LK - Sri Lanka 7
MD - Moldavia 7
Totale 56.831
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.930
Singapore 3.885
Ashburn 1.658
Ho Chi Minh City 1.574
San Jose 1.504
Dublin 1.295
Milan 1.251
Hanoi 1.233
Toronto 1.105
Chandler 807
New York 799
Chicago 751
Princeton 746
Hefei 602
Los Angeles 598
The Dalles 591
Ann Arbor 578
Frankfurt am Main 557
Santa Clara 551
Rome 513
Lauterbourg 430
Dallas 398
Beijing 352
Lawrence 291
Moscow 289
Fairfield 288
Altamura 268
Buffalo 262
Council Bluffs 254
Seoul 222
São Paulo 216
Helsinki 177
Boardman 162
Da Nang 160
Jakarta 157
Seattle 154
Wilmington 149
Andover 147
Nuremberg 147
Haiphong 143
Houston 134
Shanghai 122
San Diego 114
Cambridge 109
Figino 107
Naples 105
Woodbridge 105
Turin 100
Tokyo 96
Biên Hòa 92
Ha Long 91
Quận Bình Thạnh 91
Rio de Janeiro 91
Ninh Bình 90
London 83
Can Tho 75
Hải Dương 75
Baghdad 73
Vienna 71
Washington 70
Guangzhou 68
Thái Nguyên 68
Orem 67
Montreal 65
Salt Lake City 65
Brooklyn 64
Munich 64
Phoenix 60
Bắc Ninh 59
Pune 59
Atlanta 57
Mexico City 54
Bắc Giang 53
Columbus 53
Vũng Tàu 53
Warsaw 53
Denver 52
Bologna 51
Lappeenranta 51
San Mateo 51
Brasília 50
Tashkent 49
Dhaka 46
Elk Grove Village 46
Belo Horizonte 45
Johannesburg 45
San Francisco 45
Brussels 43
Philadelphia 43
Guayaquil 40
Istanbul 40
Kuala Lumpur 40
Quận Một 40
Boston 39
Buenos Aires 39
Charlotte 38
Riyadh 38
Miami 37
Quito 36
Amman 35
Totale 33.089
Salva come PNG Salva come JPEG
Nome #
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials 640
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial 583
Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid-range ejection fraction 545
Discrepancy in the Diagnosis of Heart Failure with Preserved Ejection Fraction between Supine Versus Upright Exercise Hemodynamic Testing 508
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes 505
Comparative effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction 469
Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: Results from an Italian multicenter study 459
Early Initiation of Sacubitril/Valsartan in Patients With Acute Heart Failure and Renal Dysfunction: An Analysis of the TRANSITION Study 447
Exploring the Prognostic Performance of MECKI Score in Heart Failure Patients with Non-Valvular Atrial Fibrillation Treated with Edoxaban 446
Clinical presentation and outcome in a contemporary cohort of patients with acute myocarditis multicenter Lombardy registry 411
A matter of sex—persistent predictive value of MECKI score prognostic power in men and women with heart failure and reduced ejection fraction: a multicenter study 355
Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years 353
Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study 350
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context 349
Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials 315
Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients 314
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure 305
Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic patients at risk for heart failure (ACCF/AHA stages A and B): Insights from the DAVID-Berg study 303
Frequency, characteristics, and outcome of patients with COVID-19 pneumonia and "silent hypoxemia" at admission: a severity-matched analysis 300
Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study 295
Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization 289
Pulmonary artery wedge pressure and left ventricular end-diastolic pressure during exercise in patients with dyspnoea 288
Current Limitations of Invasive Exercise Hemodynamics for the Diagnosis of Heart Failure With Preserved Ejection Fraction 284
Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study 280
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial 268
Clonal hematopoiesis of indeterminate potential: implications for the cardiologists 267
Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients 265
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction 253
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 237
Right Heart Adaptation to Exercise in Pulmonary Hypertension: An Invasive Hemodynamic Study 236
Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study 233
Position paper ANMCO sull'utilizzo della terapia con sacubitril/valsartan nel paziente con scompenso cardiaco [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure] 227
Haemodynamic validation of the three-step HFA-PEFF algorithm to diagnose heart failure with preserved ejection fraction 226
Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis 224
Dose-dependent efficacy of β-blocker in patients with chronic heart failure and atrial fibrillation 221
Shedding Light on Latent Pulmonary Vascular Disease in Heart Failure With Preserved Ejection Fraction 216
Right ventricular reserve in cardiopulmonary disease: A simultaneous hemodynamic and three-dimensional echocardiographic study 216
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial 216
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis 214
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 213
An uncommon and challenging finding regarding the tricuspid valve: Case report, clinical considerations, and practical management 210
Characterization of compliance phenotypes in COVID-19 acute respiratory distress syndrome 204
Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects 200
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial 200
QRS fragmentation as possible new marker of fibrosis in patients with myocarditis. Preliminary validation with cardiac magnetic resonance 194
Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO) 193
The "Early Treatment" Approach Reducing Cardiovascular Risk in Patients with Type 2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique 192
Patient adherence to drug treatment in a community based-sample of patients with chronic heart failure 192
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment 189
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 184
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF 183
Erratum: Heart failure at the crossroads: Moving beyond blaming stakeholders to targeting the heart (Eur J Heart Fail (2015) 17:8 (760-763) doi:10.1002/ejhf.315)) 180
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney Disease 177
The chronic heart failure evolutions: Different fates and routes 174
Emergency surgery of acute coronary insufficiency [La chirurgia d'urgenza nell'insufficienza coronarica acuta.] 174
Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk: an expert-based multidisciplinary Delphi consensus 172
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: Insights from the STARTregistry 169
Finerenone in Heart Failure with Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial 168
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens 167
Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system (RAAS) blockade in heart failure patients - Part I: From RAAS identification to clinical trials [Position paper della Società Italiana di Cardiologia: Il blocco del sistema renina-angiotensina-aldosterone (RAAS) nel paziente con scompenso cardiaco – Parte I: Dalla scoperta del RAAS ai trial clinici] 167
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities 165
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC 164
Exercise Right Ventricular-Pulmonary Arterial Coupling and Functional Outcome in Patients Undergoing Surgery for Secondary Ischemic Mitral Regurgitation 162
A 57-year-old man with rapidly progressive pulmonary hypertension 161
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), with the special contribution of the Heart Failure Association (HFA) of the ESC 161
Prognostic Value of sST2 in Heart Failure 159
Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19 156
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF 156
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review 153
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial 153
Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study 151
Finerenone and Atrial Fibrillation in Heart Failure A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial 150
S Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction 150
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial 149
Assistenza ventricolare sinistra dopo correzione combinata di stenosi valvolare aortica e coartazione istmica 147
Rationale for and Practical Use of Sacubitril/Valsartan in the Patient's Journey with Heart Failure and Reduced Ejection Fraction 147
Heart failure with preserved ejection fraction: Update on diagnosis and therapy [Scompenso cardiaco con frazione di eiezione preservata: Update in tema di diagnosi e terapia] 147
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF 147
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry 146
The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels 145
Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial 144
Evolocumab and clinical outcomes in patients with cardiovascular disease 144
Vasopressors and inotropes in cardiogenic shock: Is there room for "adrenaline resuscitation"? 143
The follow-up of patients undergoing percutaneous coronary intervention: Potential impact of the application of a clinical pathway-structured management on the hospital-community integration and modulated on the patient's clinical risk 143
Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial 141
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial 140
Predicting in-hospital mortality from Coronavirus Disease 2019: A simple validated app for clinical use 138
Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome 138
Multicenter Prospective Observational Study on Acute and Chronic Heart Failure One-Year Follow-up Results of IN-HF (Italian Network on Heart Failure) Outcome Registry 137
Bacterial Pericarditis due to Providencia stuartii An Atypical Case of Relapsing Pericarditis 137
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity 136
Four aces of heart failure therapy: Systematic review of established and emerging therapies for heart failure with reduced ejection fraction 135
Trattamento conservativo della valvola mitrale in presenza di endocardite infettiva 135
An unusual case of cardiac aspergillosis 134
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial 133
Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis 131
Tailored approach to trans-catheter palliation of critically reduced pulmonary blood supply. Data on long term follow up 131
Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation 131
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial 130
Cardiac contractility modulation therapy: Molecular mechanisms and rationale for clinical application in heart failure with systolic and diastolic dysfunction 129
Totale 22.613
Salva come PNG Salva come JPEG
Categoria #
all - tutte 231.832
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 231.832
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.874 0 76 77 45 88 27 28 49 41 63 1.676 704
2022/20233.988 640 1.090 282 272 208 769 54 195 273 42 95 68
2023/20243.637 68 105 98 138 590 1.004 689 92 333 95 38 387
2024/202512.162 466 1.221 441 471 1.283 473 1.104 347 1.518 1.639 946 2.253
2025/202632.457 4.379 3.430 1.888 2.627 2.724 1.395 3.931 1.451 2.079 2.286 2.509 3.758
2026/20272.377 1.621 756 0 0 0 0 0 0 0 0 0 0
Totale 58.683